Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the Pharmaceutical IndustrySpringer Science & Business Media, 19.02.2008 - 186 Seiten Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D. Our findings are illustrated not only in cases of Swiss pharmaceutical industry, but also by industry cases from the US and Asia. |
Inhalt
| 1 | |
Do You Really Want to Be in This | 19 |
How to Find | 33 |
How to Organize | 50 |
The Importance of Project and Portfolio Management | 65 |
Impact of Outsourcing on Pharmaceutical RD | 71 |
Accessing Earlystage Innovation | 78 |
Commercializing Internal Research Results | 86 |
How to Commercialize a Breakthrough Technology | 95 |
Where to Get Access | 103 |
Management Answers to Pharmaceutical RD Challenges | 123 |
Future Directions and Trends 159 | 158 |
| 165 | |
Glossary | 179 |
Andere Ausgaben - Alle anzeigen
Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the ... Oliver Gassmann,Gerrit Reepmeyer,Maximilian von Zedtwitz Keine Leseprobe verfügbar - 2010 |
Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the ... Oliver Gassmann,Gerrit Reepmeyer,Maximilian von Zedtwitz Keine Leseprobe verfügbar - 2008 |
Häufige Begriffe und Wortgruppen
Aliskiren approval AstraZeneca Aventis Bayer billion biotech biotechnology biotechnology companies blockbuster drugs blockbuster sales centers ceutical chemical China clinical development clinical trials co-development combinatorial chemistry commercialization company’s complex compound costs disease drug candidate drug development drug discovery drug’s external partners Gassmann Genentech genes genetic genomics GlaxoSmithKline global growth healthcare high-throughput screening improve in-licensing increased InnoGel Intarcia intellectual property international R&D investment know-how launch Lipitor maceutical manufacturing medicines ment molecular molecule Novartis out-licensing outsourcing overall patent protection percent Pfizer phar pharma pharmaceutical companies pharmaceutical industry pharmaceutical innovation pharmaceutical products pharmaceutical R&D pharmaceutical research pharmacogenomics pipeline portfolio potential pre-clinical Project Management proteins proteomics R&D activities R&D collaborations R&D internationalization R&D management R&D process R&D projects Reepmeyer research and development Reuters revenues risks Roche soft capsule Speedel stages strategy structure substance success Swiss Switzerland target technical evaluation technologies therapy areas tion value chain worldwide
Beliebte Passagen
Seite 169 - Newman DJ, Cragg GM, Snader KM (2003) Natural products as sources of new drugs over the period 1981-2002.
Verweise auf dieses Buch
Der Patentauslauf von Pharmazeutika als Herausforderung beim Management des ... Antje-Christina Raasch Keine Leseprobe verfügbar - 2006 |
Globalization [2 Volumes]: Encyclopedia of Trade, Labor, and Politics Ashish Vaidya Keine Leseprobe verfügbar - 2006 |